Detail akcie BIOMED-LUBLIN online

Business Summary: Synthaverse SA is a Poland-based company primarily engaged in the biopharmaceutical and pharmaceutical manufacturing industry. The Company focuses on the development, manufacture, and commercialization of biological medicinal products, vaccines, immunotherapies, probiotics, and laboratory reagents. It offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. Its activities also include biotechnology research and development, pharmaceutical substance manufacturing, packaging services, and selected healthcare-related services.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Synthaverse SA revenues increased 34% to PLN26.5M. Net loss increased 20% to PLN6.4M. Revenues reflect Traditional Segment increase of 70% to PLN9.9M, BCG Segment increase of 19% to PLN16.6M, Other Countries segment increase of 81% to PLN8.8M, European Union (Region) segment increase of 55% to PLN10.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -PLN0.07496 to -PLN0.08402.